Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History ATRA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics ATRA

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Atara Biotherapeutics Inc

ATRA
Current price
9.28 USD +0.08 USD (+0.87%)
Last closed 9.27 USD
ISIN US0465131078
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 66 167 460 USD
Yield for 12 month -11.66 %
1Y
3Y
5Y
10Y
15Y
ATRA
21.11.2021 - 28.11.2021

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California. Address: 1280 Rancho Conejo Blvd, Thousand Oaks, CA, United States, 91320

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

16.00 USD

P/E Ratio

Dividend Yield

Financials ATRA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures ATRA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+128 940 000 USD

Last Year

+8 573 000 USD

Current Quarter

+98 149 000 USD

Last Quarter

+32 753 000 USD

Current Year

+107 931 000 USD

Last Year

-313 000 USD

Current Quarter

+77 710 000 USD

Last Quarter

+25 958 000 USD
EBITDA 2 235 000 USD
Operating Margin TTM 49.53 %
Price to Earnings
Return On Assets TTM -1.77 %
PEG Ratio
Return On Equity TTM -2 014.86 %
Wall Street Target Price 16.00 USD
Revenue TTM 199 732 000 USD
Book Value -9.30 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 258.80 %
Dividend Yield
Gross Profit TTM 35 564 000 USD
Earnings per share -2.26 USD
Diluted Eps TTM -2.26 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -7.83 %

Stock Valuation ATRA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 3.63
Enterprise Value Revenue 0.41
Price Sales TTM 0.33
Enterprise Value EBITDA -0.35
Price Book MRQ 1.97

Technical Indicators ATRA

For 52 Weeks

5.01 USD 18.71 USD
50 Day MA 7.92 USD
Shares Short Prior Month 285 774
200 Day MA 8.83 USD
Short Ratio 3.89
Shares Short 266 647
Short Percent 6.08 %